> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA to Permit In-Person End-of-Phase 2 Meetings
- URL: https://www.fdaweb.com/fda-to-permit-in-person-end-of-phase-2-meetings/
- Published: 2023-05-31T12:00:00.000Z
- Updated: 2026-09-14T18:35:13.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5154585

FDA continues to ramp up its return to face-to-face (FTF) meetings and beginning 6/12 CDER and CBER will expand in-person FTF industry meetings to include requests for Type B End-of-Phase 2 requests. The End-of-Phase 2 requests join the previously announced Type A, BPD Type 1, and Type X meeting requests, according to a [new notice](https://www.fda.gov/industry/prescription-drug-user-fee-amendments/update-person-face-face-formal-meetings-fda?utm%5Fmedium=email&utm%5Fsource=govdelivery). Type A meetings are those that are necessary for a stalled drug development program to proceed. A BPD Type 1 meeting is a meeting that is necessary for a stalled biosimilar product development program to proceed. And a Type X meeting is necessary for an otherwise stalled OTC monograph development program to proceed.

“FTF meeting requests for other meeting types, if granted, will be held fully virtually (i.e., the in-person format will not be considered),” the agency says. Existing meeting requests filed before 6/12/2023 or meetings already scheduled regardless of the scheduled meeting date, “will not be converted to the in-person format, to permit fair implementation of the transition,” it says.